GMP, manufacturing authorisation and product approval

The facility and its activities

A manufacturing authorisation concerns the activities a specified manufacturer or site may undertake. WHO GMP main principles address the standards used in assessing and inspecting pharmaceutical manufacturing. The scope and status of the actual authorisation or certificate need to be read directly.

In due diligence, ask which legal entity and physical site the document identifies, which activities or dosage forms it covers, which authority issued it and what dates or conditions apply. A certificate associated with one site should not be attributed to a different site merely because the companies are related.

The product authorisation

A product approval concerns an identified medicine and its supporting submission. It is not the same as a site-level manufacturing permission. The dossier connects the product’s formulation and presentation with the information considered by the relevant authority.

A facility can have an authorised scope without every portfolio idea being approved. Equally, a publication describing an established active substance does not prove that a proposed product using it has completed the required review. The exact strength and presentation matter.

Quality continues beyond a single document

ICH Q10: Pharmaceutical Quality System describes a lifecycle quality-system model, including product and process monitoring, corrective and preventive action, change management and management review. ICH Q9(R1): Quality Risk Management explains the role of risk assessment and the need to scale formality to the nature of the risk.

For a counterparty, those references help frame questions about how the particular operation is controlled. They do not establish that a company has implemented the systems simply because it cites the guidelines. Documentary claims should connect to the site, process and period under discussion.

The batch and its evidence

A certificate of analysis reports specified information or test results for an identified material or batch. Its meaning depends on the product identity, specification, method, results and issuing party. It does not by itself answer every question about manufacture, product approval or legal market access.

If a certificate is supplied, compare its identifiers with the other transaction documents. Ask whether it refers to the finished product or to a raw material, and whether the formulation and batch details match the proposed goods. A document headed “certificate” is not self-explanatory.

The destination remains a separate question

A product’s status in one jurisdiction does not automatically determine what may happen in another. The import, distribution and intended use of the goods must fit the destination’s lawful pathway and the responsibilities of the parties involved.

The registration and export guide explains this distinction in more detail. A freight arrangement or commercial invoice cannot replace the regulatory basis for the transaction.

Applying the distinctions to a developing facility

At a construction-stage project, review the physical programme and the evidence for each claimed milestone separately. Planned capacity describes engineering intent; installation describes equipment at a site; qualification and validation require their own evidence; licensing and product approvals require decisions from the competent authorities.

Luang Pharma’s Boten facility is under construction. Its public portfolio is a development catalogue. The quality and regulatory pages explain the workstreams in the project plan without treating them as completed operating permissions.

Four separate due-diligence questions

Ask separately: is the site authorised for the relevant activity; is its GMP status current for the relevant scope; is the exact product authorised in the relevant market; and is the particular batch supported by release and quality documentation? One affirmative answer does not automatically answer the other three.

Inspection reports, GMP certificates, manufacturing authorisations, marketing authorisations and certificates of analysis have different issuers, scopes and validity conditions. A professional review should record which document was seen, who issued it, what site or product it covers and whether the date and scope are current.

Certificates support decisions; they do not replace them

The WHO Certification Scheme for pharmaceutical products moving in international commerce is a regulatory-cooperation tool. Its certificates can convey information relevant to authorities, but destination regulators retain their own legal responsibilities and may require additional evidence. A certificate should therefore be read within the scheme and the destination process that uses it.

For Luang Pharma, no public page should convert a planned quality system, external guideline or future document request into a claim that a current GMP certificate, marketing authorisation or batch release exists. Those statuses require the actual controlled evidence.

Sources and further reading

Source links and editorial scope checked 11 September 2026. External sources remain attributable to their issuers and do not establish Luang Pharma product or facility status.